IAV-S and the impact on growing pigs

Growing pigs in the U.S. face the threat of numerous respiratory pathogens throughout their growing period, creating a significant impact on productivity and profitability.1

It has been shown that when uncomplicated, influenza A virus in swine (IAV-S) can lead to an estimated loss of more than $3 per pig.1 When present with concurrent infections, such as porcine reproductive and respiratory syndrome virus (PRRSV), the loss can be greater than $10 per pig.1

Until now, phase-specific respiratory pathogen burden, from the time of weaning to marketing, has not been well characterized. This poses a considerable challenge to producers to effectively evaluate the association between the timing, duration, and concurrent infection of key respiratory disease agents and performance outcomes.

A recent study reported by Iowa State University analyzed the burden of respiratory disease during the growing period as it relates to multiple pathogens, IAV-S as well as PRRSV.2

Studying pathogen burdens through production
The study described by Iowa State University measured pathogen burden from oral fluid sampling. Forty-five flows (independent groups of pigs) were sampled every 2 weeks from nursery placement through closeout. The results of these diagnostics determined three main “patterns” of burden for each pathogen. The study then coupled the diagnostic data with the total mortality data reported for each enrolled group.

Pathogen Burden Chart

Pathogen Burden Chart

Associated mortality2
Flows that were seen to have growing nursery pathogen burdens (pattern 2, moving from low to moderate-high pathogen burden in the nursery) had the highest average mortality rates; over 40% greater than any other pattern for IAV-S, and 80% greater than any other pattern for PRRSV. Based on these mortality rates, average daily gain (ADG) for the affected flows would be expected to be significantly lower.

In flows that fit both IAV-S pattern 2 and PRRSV pattern 2, this compounded late nursery pathogen burden affected overall mortality rates even more, climbing from 10.4% and 10.1%, respectively, for the individual pathogens to a combined 13.7%.

Controlling IAV-S leads to better health outcomes1
The presence of an increased burden of respiratory pathogens inevitably leads to increased numbers of diseased pigs. When pigs are affected by respiratory disease, lost productivity has been shown to impact the ability of pigs to reach their full potential.1

Ensuring that young pigs are protected against IAV-S through all production phases is crucial for maintaining optimal productivity. For more information on vaccination control strategies, visit www.aboutswineinfluenza.com.

Disclaimer

WELCOME TO INGELVACPROVENZA.COM

Are you located within the United States of America?
ARE YOU A VETERINARIAN?

This is a required field

This website is an international information resource intended for veterinarians who are interested in information about Ingelvac Provenza™ and influenza A virus in swine.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product label may not be the same in different countries.

INGELVAC PROVENZA™ IS ONLY CURRENTLY LICENCED IN THE UNITED STATES OF AMERICA. Information on this website is derived from the product label in the USA.

By checking the box below, you are declaring and confirming that you are a veterinarian professional and that you have read and understood this disclaimer.

You must accept the terms and conditions and data policy to enter the website

Ingelvac Provenza is a trademark of Boehringer Ingelheim Vetmedica GmbH. © 2018 Boehringer Ingelheim Vetmedica, Inc.